How GLP-1s tanked and reshaped the medtech stock market | Mass Device

Aug 1, 2024

chart

Promising clinical trial results on glucagon-like peptide 1 agonists (GLP-1s) created a seismic shift in the medtech stock market.

Source: How GLP-1s tanked and reshaped the medtech stock market | Mass Device

Hire with SEC


Schedule a free consultation today to experience our innovative, industry-leading executive search and engineer recruiting hiring process firsthand.

"*" indicates required fields

Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Pin It on Pinterest